ReviewDrugs2005
What is potent acid inhibition, and how can it be achieved?
Review in Drugs, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Comparison of different regimens of proton pump inhibitors for acute peptic ulcer bleeding.The Cochrane database of systematic reviews · 2013Pooled it
- Evaluation of Proton Pump Inhibitor Esomeprazole on Crizotinib Pharmacokinetics in Healthy Participants.Clinical pharmacology in drug development · 2022Trial
- Efficacies of different proton pump inhibitor-based 14-day bismuth-furazolidone quadruple regimens for the initial eradication of Helicobacter pylori in the southeast coastal region of China: an open-label, randomized clinical trial.Clinical and experimental medicine · 2018Trial
- Comparative study of esomeprazole and lansoprazole in triple therapy for eradication of Helicobacter pylori in Japan.World journal of gastroenterology · 2014Trial
- Comparative renal safety: potassium-competitive acid blockers vs proton pump inhibitors.Clinical kidney journal · 2026Article
- Association between proton pump inhibitor use and muscle mass: a US population-based study.Aging clinical and experimental research · 2026Article
- Vonoprazan-based bismuth quadruple therapy for first-line Helicobacter pylori eradication: A real-world, retrospective study.Medicine · 2026Article
- Single Capsule Bismuth Quadruple Therapy for Eradication ofFrontiers in pharmacology · 2021Article
- Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility.Journal of gastroenterology · 2020Article
- Comparative study: Vonoprazan and proton pump inhibitors inWorld journal of gastroenterology · 2017Article
- The role of pH in symptomatic relief and effective treatment of gastroesophageal reflux disease.Przeglad gastroenterologiczny · 2017Review
- Esomeprazole- or rabeprazole-based triple therapy eradicatedJournal of clinical biochemistry and nutrition · 2016Article
- Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori.The Kaohsiung journal of medical sciences · 2016Article
- Medical treatment of gastrinomas.Wiener klinische Wochenschrift · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinical response to antisecretory treatment correlates directly with the degree of inhibition of acid secretion achieved. Acid inhibition able to maintain the intragastric pH at a value greater than 4 for at least 16 h/day seems to heal even the most refractory acid-related diseases. It has also been shown that the degree of inhibition of acid secretion in response to antisecretory treatment depends on the genetic characteristics of the patient and on the presence of Helicobacter pylori infection. A possible definition of potent (or profound) acid inhibition is, therefore, the achievement of the aforementioned level of control of acid secretion regardless of patient characteristics or of the presence of H. pylori infection. Antisecretory drugs differ in their ability to reach potent acid inhibition. As far as the comparative efficacy of different drugs for inhibiting acid secretion is concerned, proton pump inhibitors are more efficient in inhibiting gastric acid secretion than histamine (H2) receptor antagonists. Among the different proton pump inhibitors, esomeprazole 40 mg/day exhibits greater antisecretory potency than the others at standard doses. Rabeprazole 20 mg/day and lansoprazole 30 mg/day exhibit a more rapid onset of action than omeprazole 20 mg/day or pantoprazole 40 mg/day.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.